CIK 0001557746 · Non-accelerated filer<br>Smaller reporting company
Aclaris Therapeutics, Inc.
Sign in to watch- Ticker
- ACRS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460571712
- Phone
- 484-324-7933
- Business address
- 701 LEE ROAD, SUITE 103, WAYNE, PA, 19087
- 4 Open-market sale Director sold 59,240 shares at an average $12.50 ($740,658)
- 4 Open-market sale Chief Scientific Officer sold 30,837 shares at an average $12.51 ($385,639)
- 4 Open-market sale Chief Financial Officer sold 1,894 shares at an average $12.45 ($23,579)
- 8-K Event Material agreement · Agreement ended
- 424B5 Offering Prospectus
- 10-K Report Annual Report
- 8-K Event Results of operations
- 4 Open-market sale Chief Scientific Officer sold 5,000 shares at $13.06 ($65,311)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Chief Business Officer sold 4,267 shares at $13.89 ($59,272)
- SC 13G/A Stake Amended Statement of Ownership
- 4 Open-market sale Director sold 30,000 shares at an average $16.66 ($499,923)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Option exercise Chief Business Officer acquired 11,250 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- SC 13G/A Stake Amended Statement of Ownership
Page 14 of 44 · 872 filings